Unlock AI-driven, actionable R&D insights for your next breakthrough.

L-Methionine Appearance: Comprehensive Analysis Of Physical Characteristics, Crystalline Properties, And Quality Control Parameters

NOV 17, 202666 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
L-Methionine appearance encompasses critical physical attributes that directly influence its handling, formulation, and application in pharmaceutical, nutraceutical, and feed industries. As an essential amino acid produced through fermentation or chemical synthesis, L-Methionine typically presents as white to off-white crystalline powder with specific particle size distributions, bulk density characteristics, and morphological features that determine its flowability, compressibility, and bioavailability 1,6. Understanding these appearance-related properties is fundamental for R&D professionals optimizing production processes, ensuring regulatory compliance, and developing superior formulations with enhanced performance metrics.
Want to know more material grades? Try Patsnap Eureka Material.

Fundamental Physical And Morphological Characteristics Of L-Methionine Appearance

The appearance of L-Methionine is primarily defined by its crystalline structure and particle characteristics, which emerge from both its molecular architecture and the production methodology employed. L-Methionine produced via fermentation routes exhibits distinct appearance profiles compared to chemically synthesized D,L-racemates, with the former typically yielding higher purity crystals with more uniform morphology 1,2. Key Physical Descriptors:

  • Color and Visual Characteristics: Pure L-Methionine appears as white to slightly off-white crystalline powder. The presence of trace impurities from fermentation media—including residual amino acids (glutamic acid, valine, isoleucine, leucine, tyrosine, phenylalanine, threonine) at concentrations ≥0.05%—can impart subtle color variations 4,14. High-purity grades (>95% purity) demonstrate brilliant white appearance with minimal discoloration 4.
  • Crystalline Morphology: L-Methionine crystallizes in characteristic needle-like or prismatic forms depending on crystallization conditions (temperature, supersaturation ratio, cooling rate, and solvent system). Advanced crystallization techniques can produce crystals with optimized aspect ratios that enhance bulk density up to 800 g/L, significantly improving storage efficiency and powder flowability 6.
  • Surface Characteristics: Scanning electron microscopy (SEM) analysis reveals that fermentation-derived L-Methionine typically exhibits smoother crystal surfaces compared to chemically synthesized variants, which may show surface irregularities or agglomeration tendencies due to residual process chemicals 2,7. The appearance profile is critically influenced by downstream processing parameters. For instance, controlled crystallization at specific temperature gradients (typically 5-15°C/hour cooling rate) and pH ranges (4.5-6.0) yields crystals with superior appearance uniformity and reduced fines content 6.

Particle Size Distribution And Its Impact On L-Methionine Appearance

Particle size distribution (PSD) represents one of the most critical appearance-related parameters for L-Methionine, directly affecting bulk density, flowability, dust generation, and formulation behavior. Recent patent literature provides detailed specifications for optimized PSD profiles that balance handling properties with application requirements 9,11. Optimized Particle Size Specifications: For D,L-Methionine (applicable principles extend to L-Methionine), advanced formulations demonstrate the following PSD characteristics 9,11:

  • Fine Fraction (0-150 μm): 15 to <50 wt.% ensures adequate surface area for dissolution while minimizing dust hazards during handling. Excessive fines (<32 μm fraction should remain <20 wt.%) can compromise flowability and create electrostatic charging issues 9.
  • Medium Fraction (150-300 μm): 50 to <90 wt.% (preferably 50-70 wt.%) constitutes the core particle population, providing optimal balance between bulk density and compressibility. The 63-300 μm range specifically should comprise 30-80 wt.% for superior flow characteristics 9,11.
  • Coarse Fraction (300-500 μm): 10-45 wt.% contributes to bulk density enhancement (achieving ≥710 kg/m³) and reduces segregation tendencies in blended formulations 9,11.
  • Oversize Particles (>500 μm): Limited to 1-20 wt.% (500-710 μm range) and <2 wt.% (>1000 μm) to prevent sieving effects and ensure uniform mixing in feed applications 9,11. Measurement and Control: Particle size analysis should employ laser diffraction techniques (ISO 13320 standard) with appropriate dispersion methods to prevent agglomeration artifacts. The appearance of particle size distributions can be visually assessed through optical microscopy, revealing the proportion of needle-like crystals versus more equiaxed forms, which correlates with crystallization kinetics and supersaturation history 6. Manufacturing processes incorporating controlled crystallization, followed by classification (air classification or sieving) and optional milling, enable precise PSD targeting. The resulting appearance—from fine powder to coarse granular material—must align with end-use requirements: pharmaceutical tablets demand tighter PSD control (typically 100-300 μm) for content uniformity, while feed premixes tolerate broader distributions 6,9.

Bulk Density And Flow Properties Related To L-Methionine Appearance

Bulk density, an appearance-related property directly observable through volume-to-mass relationships, critically impacts storage, transportation economics, and processing behavior. L-Methionine with optimized appearance characteristics achieves bulk densities of 710-800 kg/m³, representing 15-25% improvement over conventional products 6,9. Factors Influencing Bulk Density:

  • Crystal Habit and Aspect Ratio: Needle-like crystals with high aspect ratios (length:width >5:1) exhibit lower bulk densities (500-600 kg/m³) due to inefficient packing, while more equiaxed crystals (aspect ratio 2:1 to 3:1) achieve denser packing arrangements 6. Crystallization process modifications—including seeding strategies, impurity addition (crystal habit modifiers), and controlled cooling profiles—can manipulate crystal habit to optimize appearance and density 6.
  • Particle Size Distribution: As detailed above, PSD directly governs packing efficiency. Bimodal or trimodal distributions, where smaller particles fill interstitial spaces between larger crystals, maximize bulk density while maintaining acceptable flow properties 9,11.
  • Moisture Content: L-Methionine appearance can be affected by moisture absorption (hygroscopicity), which promotes particle agglomeration and alters flow behavior. Properly dried L-Methionine (<0.2% moisture content) maintains free-flowing appearance, while moisture levels >0.5% can cause caking and density reduction 6. Flow Characterization: The visual appearance of L-Methionine powder flow can be quantified through:
  • Angle of Repose: Free-flowing L-Methionine exhibits angles of 25-35°, while cohesive materials show >40° 6.
  • Hausner Ratio: Values <1.25 indicate good flowability, correlating with uniform appearance in hoppers and feeders 6.
  • Compressibility Index (Carr's Index): Values <15% suggest excellent flow, directly observable as smooth, continuous discharge from containers 6. These flow-related appearance characteristics are essential for automated processing in pharmaceutical tableting, feed mixing, and packaging operations, where bridging or rat-holing would disrupt production continuity.

Chemical Purity And Appearance Correlation In L-Methionine Products

The appearance of L-Methionine serves as a preliminary indicator of chemical purity, though comprehensive analytical characterization remains essential. High-purity L-Methionine (>98%) typically exhibits brilliant white color, uniform crystal size, and absence of discoloration, while lower grades may show yellowish tints or heterogeneous appearance 1,4. Purity-Related Appearance Indicators:

  • Color Uniformity: Pure L-Methionine demonstrates consistent white appearance across batches. Yellow or brown discoloration may indicate oxidation products, Maillard reaction byproducts (in fermentation-derived material), or residual process impurities 2,4.
  • Crystal Clarity: Transparent to translucent crystals suggest high purity, while opaque or cloudy appearance may indicate inclusion of mother liquor, salt co-precipitation, or amorphous content 6.
  • Absence of Foreign Particles: Visual inspection under magnification should reveal uniform crystalline material without colored specks, which could represent microbial contamination (in fermentation products) or catalyst residues (in chemical synthesis) 1,2. Analytical Correlation: Advanced L-Methionine products demonstrate the following purity specifications, which correlate with superior appearance 4,14,16:
  • L-Methionine Content: ≥98.5% (HPLC analysis), with D-Methionine content <2% for fermentation-derived products 4.
  • Residual Amino Acids: Total non-methionine amino acids <0.3%, individually <0.1% (glutamic acid, valine, isoleucine, leucine, tyrosine, phenylalanine, threonine) 4,14.
  • Carboxylic Acids: Acetic acid (from O-acetylhomoserine pathway) <0.05%, other carboxylic acids <0.01% 4,14.
  • Sulfate: <0.03% (from fermentation media or neutralization steps) 4.
  • Heavy Metals: <10 ppm total, with specific limits for Pb (<2 ppm), As (<1 ppm), Cd (<1 ppm) per pharmaceutical compendia 3.
  • O-Acetylhomoserine (OAHS): <1 ppb in finished product, as this precursor can affect appearance through hygroscopicity and discoloration tendencies 4,14. Products meeting these specifications consistently demonstrate optimal appearance characteristics, facilitating visual quality control and reducing rejection rates in pharmaceutical and food applications.

Production Methods And Their Influence On L-Methionine Appearance

The appearance of L-Methionine is fundamentally determined by the production route—fermentation versus chemical synthesis—and subsequent purification and crystallization processes. Each methodology imparts distinct appearance signatures that R&D professionals must understand for process optimization and quality assurance 1,2,5.

Fermentation-Derived L-Methionine Appearance Characteristics

Fermentation processes utilizing genetically modified bacteria (Escherichia coli, Corynebacterium glutamicum) produce exclusively L-Methionine through metabolic pathways involving O-acetylhomoserine or O-succinylhomoserine intermediates 1,5,8. The appearance of fermentation-derived L-Methionine reflects both the biological production system and downstream recovery operations 1,2. Process-Appearance Relationships:

  • Fermentation Broth Composition: Residual nutrients (amino acids, carboxylic acids, salts) at concentrations of 0.05-0.3% can co-precipitate during crystallization, affecting crystal purity and appearance 4,14. Advanced purification employing ion-exchange chromatography or selective crystallization minimizes these impurities, yielding brilliant white crystals 2,7.
  • Enzymatic Conversion Steps: Two-stage processes where O-acetylhomoserine reacts with methanethiol via sulfhydrylase enzymes produce L-Methionine with acetate as byproduct 2,7,12. Incomplete acetate removal can cause hygroscopicity and appearance deterioration during storage 4,14.
  • Cell Debris and Protein Removal: Effective biomass separation (centrifugation, microfiltration) and protein precipitation (heat treatment, pH adjustment, or enzymatic hydrolysis) are critical for achieving clear mother liquors that crystallize into uniform, white L-Methionine crystals 1,2. Crystallization Optimization: Controlled crystallization from fermentation-derived solutions typically employs:
  • Cooling Crystallization: Gradual temperature reduction (40-50°C to 5-10°C at 5-15°C/hour) with seeding at 5-10% supersaturation yields uniform needle or prismatic crystals with minimal fines 6.
  • pH Adjustment: Crystallization at pH 5.0-6.0 (near L-Methionine isoelectric point of 5.74) maximizes yield and crystal purity, producing white, free-flowing powder 6.
  • Anti-Solvent Addition: Ethanol or isopropanol addition (10-30% v/v) can enhance crystallization kinetics and modify crystal habit, affecting final appearance 6. The resulting fermentation-derived L-Methionine typically exhibits:
  • Brilliant white color (L* value >92 in CIELAB color space)
  • Narrow particle size distribution (CV <30%)
  • Bulk density 650-800 kg/m³ (optimized processes)
  • Low dust generation (<5% <63 μm fraction) 1,6

Chemical Synthesis And Racemic Mixture Appearance

Chemical synthesis produces D,L-Methionine racemates requiring resolution for pharmaceutical applications 2. The appearance of chemically synthesized material differs from fermentation products due to process chemistry and impurity profiles 2,9. Synthesis-Related Appearance Factors:

  • Hydantoin Route: The predominant chemical method involves hydrolysis of 5-(β-methylmercaptoethyl)-hydantoin, producing D,L-Methionine with potential residual hydantoin derivatives that can impart off-white to cream coloration 2.
  • Catalyst Residues: Chemical synthesis may employ metal catalysts (Ni, Pd) or strong acids/bases, with residual traces affecting crystal appearance and requiring stringent purification 2.
  • Racemic Crystal Structure: D,L-Methionine can crystallize as conglomerates (separate D and L crystals) or racemic compounds, with different appearance characteristics. Racemic compounds typically show more uniform, equiaxed crystal habit compared to conglomerates 2. Optimized D,L-Methionine products demonstrate particle size distributions as detailed in patents 9,11, achieving bulk densities ≥710 kg/m³ through controlled crystallization and classification. However, the presence of D-enantiomer (50% in unresolved racemate) limits pharmaceutical applications, necessitating enzymatic or chromatographic resolution for L-Methionine isolation 2.

Analytical Methods For Characterizing L-Methionine Appearance

Comprehensive appearance characterization of L-Methionine requires integration of visual assessment, microscopic examination, and instrumental analysis to quantify physical properties and ensure batch-to-batch consistency 6,9,13.

Visual And Microscopic Evaluation

Macroscopic Inspection:

  • Color Assessment: Comparison against reference standards using standardized lighting (D65 illuminant, 6500K color temperature) and color measurement instruments (spectrophotometers measuring Lab* values). Acceptable L-Methionine shows L* >90, a* and b* values near zero 6.
  • Particle Appearance: Visual evaluation of crystal form (needle, prismatic, plate), size uniformity, and presence of agglomerates or foreign matter using magnifying lenses (10-20× magnification) 6. Microscopic Characterization:
  • Optical Microscopy: Polarized light microscopy reveals crystal birefringence, habit, and size distribution. Particle size analysis via image analysis software provides quantitative PSD data complementing laser diffraction results 6.
  • Scanning Electron Microscopy (SEM): High-resolution imaging (1000-10,000× magnification) characterizes crystal surface morphology, identifies surface defects or coatings, and distinguishes between primary crystals and agglomerates. Energy-dispersive X-ray spectroscopy (EDS) coupled with SEM can detect surface contamination affecting appearance 6.

Instrumental Physical Property Analysis

Particle Size Distribution:

  • Laser Diffraction: ISO 13320-compliant analysis using instruments like Malvern Mastersizer or Horiba LA-960 provides volume-weighted PSD from 0.1-3000 μm. Dry dispersion methods are preferred for free-flowing L-Methionine to avoid dissolution artifacts 9,11.
  • Sieve Analysis: ASTM E11-compliant sieving (mesh sizes: 32, 63, 100, 150, 200, 300, 500, 710, 1000 μm) offers direct mass-based PSD measurement, particularly useful for coarse fractions >100 μm 9,11. Bulk And Tapped Density:
  • Bulk Density Measurement: USP <616> method using 100-250 mL graduated cylinders, measuring mass of freely settled powder. Target values: 650-800 kg/m³ for optimized L-Methionine 6,9.
  • Tapped Density: Automated tapping (typically 500-1250 taps
OrgApplication ScenariosProduct/ProjectTechnical Outcomes
CJ CHEILJEDANG CORPORATIONPharmaceutical formulations, nutraceutical applications, and animal feed premixes requiring superior flowability, reduced storage/transport costs, and enhanced content uniformity in tablet manufacturing.L-Methionine Crystalline ProductOptimized crystallization technique achieving bulk density up to 800 g/L with controlled particle size distribution (50-70 wt% in 0-300 μm range, 30-80 wt% in 63-300 μm range), brilliant white appearance (L* value >92), and purity >98.5% with residual amino acids <0.3%.
AJINOMOTO CO. INC.Pharmaceutical applications requiring chiral pure L-amino acid, medical solutions, food additives, and feed supplements where enantiomeric purity is critical for bioavailability and regulatory compliance.Fermentation-derived L-MethionineGenetically modified bacterial fermentation producing exclusively L-enantiomer with <2% D-methionine content, white to off-white crystalline powder with uniform morphology, narrow particle size distribution (CV <30%), and high purity (>95%).
Evonik Operations GmbHAnimal feed industry applications requiring efficient mixing, automated processing in hoppers and feeders, reduced segregation in blended formulations, and improved handling properties in large-scale production facilities.D,L-Methionine Optimized PowderAdvanced particle size distribution with bulk density ≥710 kg/m³, comprising 15-50 wt% fine fraction (0-150 μm), 50-90 wt% medium fraction (0-300 μm), achieving excellent flowability (angle of repose 25-35°, Hausner ratio <1.25) and minimal dust generation (<5% <63 μm fraction).
Arkema FranceSustainable L-methionine production for pharmaceutical and food industries requiring reduced environmental impact, lower ATP/NADPH consumption, and exclusively L-enantiomer output without racemic mixture resolution.Enzymatic L-Methionine Production SystemTwo-stage biotechnological process using O-acetylhomoserine and methanethiol via sulfhydrylase enzymes, producing L-methionine with smooth crystal surfaces, transparent to translucent appearance indicating high purity, and reduced energy consumption compared to complete fermentation routes.
BASF AGIndustrial-scale fermentation facilities for efficient L-methionine biosynthesis in pharmaceutical manufacturing, feed additive production, and nutraceutical applications requiring consistent batch-to-batch quality and high volumetric productivity.Enhanced L-Methionine Fermentation PlatformGenetically engineered microorganisms with reduced homolanthionine formation and optimized MetB/McbR regulation, producing high-purity L-methionine with uniform white crystalline appearance, enhanced secretion efficiency, and minimized by-product accumulation.
Reference
  • Method for producing l-methionine using a bacterium
    PatentInactiveUS20210207182A1
    View detail
  • Method for producing l-methionine
    PatentActiveSG11201802624YA
    View detail
  • Composition containing l-methionine and additives for use as a medicament
    PatentInactiveIL103152A
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png